It looks like nothing was found at this location. Maybe try one of the links below or a search?
Popular Articles:
-
Response to EPO consultation: Don’t impose oral proceedings by videoconference
-
Quality at the EPO – One Modest and one Serious Proposal
-
‘Opposition against Unitary Patent comes from fearful lawyers and critics who only have a theoretical interest’
-
Leading German patent law firms criticize European Patent Office
-
UPC: four reasons on why the PPA is not legally in force
-
The EPO’s Vision (V) – Trust
Recent Articles:
-
Announcement of the national program “MOVER” raises expectations for an increase in patent filings for green technology
-
UPC “saisie-contrefaçon” Part III: the “C-Kore” case
-
Brazil: Animal Health and Patent Litigation
-
China’s Supreme People Court decides FRAND dispute in ACT v Oppo
-
UPC “saisie-contrefaçon” Part II: the “OERLIKON” case
-
UPC “saisie-contrefaçon” Part I: the texts
Random Articles:
-
Patent litigation around the kitchen: from ancient Greece to Thermomix.®
-
EPO management fails to allow mass emails, despite ILOAT judgment
-
Covid: US backs waiver on vaccine intellectual property
-
TQ Delta Injunction
-
An Enlarged Board of Appeal problem
-
Treatment by surgery, European Patent Office (EPO Enlarged Board of Appeal), 15 February 2010
-
Recent Indian Case Law on Standard Essential Patents
-
Neutrokine/HUMAN GENOME SCIENCES, European Patent Office (EPO Board of Appeal), 21 October 2009
-
UK: Occlutech v. AGA, Court of Appeal Civil Division, 22 June 2010
-
Austria, Belgium, Extent of Protection, France, Germany, Norway, Scope of protection, SPC, United Kingdom
SPC – Novartis v Actavis (valsartan): the sequel